As expected or suspected20 Aug 2025 10:08
RNS Number : 0840W
Sareum Holdings PLC
20 August 2025
Sareum Holdings plc
("Sareum" or the "Company")
Exercise of Warrants
Cambridge, UK, 20 August 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has received notices to exercise certain warrants to subscribe for a total of 1,404,040 new ordinary shares in the capital of the Company at a price of 12.5 pence per ordinary share ("New Ordinary Shares") for a total consideration to the Company of £175,505.
Admission and Total Voting Rights
Application has been made to the London Stock Exchange plc for the admission of the 1,404,040 New Ordinary Shares to trading on AIM ("Admission"). It is expected that Admission will occur at 8.00 a.m. (London time) on or around Tuesday 26 August 2025. The New Ordinary Shares will rank pari passu with the existing ordinary shares.
Immediately following Admission, the total number of ordinary shares in issue will be 136,815,933. and the total number of voting rights will therefore be 136,815,933, and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.